Dec 02, 2019
Eisai and Biogen's Joint Investigational Asset BAN2401 Data to be Presented at Clinical Trials on Alzheimer's Disease Conference
Dec 02, 2019
BioArctic and Eisai to Present Data on BAN2401 at the Clinical Trials on Alzheimer's Disease Conference
Nov 07, 2019
ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's disease
Oct 24, 2019
ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease
Oct 22, 2019
Neurimmune Welcomes Biogen's News on Clinical Benefit of Aducanumab
Apr 12, 2019
Innoplexus' Clinical Trial Prediction Engine Predicted Aducanumab Failure
Mar 21, 2019
Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease
Mar 15, 2019
ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results
Nov 13, 2018
ProMIS Neurosciences Announces Third Quarter 2018 Results
Aug 21, 2018
ProMIS Neurosciences Oligomer Selective Antibody Therapeutic for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies in Clinical Development
Jul 25, 2018
Eisai And Biogen Announce Detailed Results Of Phase II Clinical Study Of BAN2401 In Early Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018
Jul 25, 2018
Eisai And Biogen Present Detailed Results From Phase II Clinical Study Of Elenbecestat In MCI And Mild To Moderate Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018
Jul 18, 2018
Eisai To Present Latest Data On Alzheimer's Disease / Dementia Pipeline At Alzheimer's Association International Conference 2018
Jul 05, 2018
Eisai And Biogen Announce Positive Topline Results Of The Final Analysis For BAN2401 At 18 Months
May 11, 2018
ProMIS Neurosciences Announces First Quarter 2018 Results
Mar 14, 2018
ProMIS Neurosciences Announces Fiscal Year 2017 Annual Results
Mar 06, 2018
ProMIS Neurosciences Lead Product Candidate for Alzheimer's Disease Shows Potential for Improved Therapeutic Potency versus Other Amyloid Beta-Directed Antibodies
Jan 25, 2018
ProMIS Neurosciences Issues White Paper Entitled: "Not All Amyloid Beta Therapeutics Are Created Equal"
Jan 23, 2018
ProMIS Neurosciences Lead Product Candidate for Alzheimer's Disease Shows Potential for Improved Therapeutic Potency versus Other Amyloid Beta-Directed Antibodies
Jan 04, 2018
ProMIS Neurosciences Lead Product Candidate for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies